Last reviewed · How we verify
triamcinolone intravitreal injection
triamcinolone intravitreal injection is a corticosteroid Small molecule drug developed by Federal University of São Paulo. It is currently in Phase 3 development for Treatment of non-infectious uveitis affecting the posterior segment of the eye, Treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion. Also known as: triamcinolone.
Triamcinolone intravitreal injection works by releasing a corticosteroid into the eye to reduce inflammation.
Triamcinolone intravitreal injection is used to treat conditions such as Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, and Diabetic Macular Edema. It is administered directly into the eye as an intravitreal injection.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | triamcinolone intravitreal injection |
|---|---|
| Also known as | triamcinolone |
| Sponsor | Federal University of São Paulo |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The corticosteroid, triamcinolone, has potent anti-inflammatory properties that help to reduce swelling and inflammation in the eye. This can help to alleviate symptoms associated with conditions such as macular edema and uveitis.
Approved indications
- Treatment of non-infectious uveitis affecting the posterior segment of the eye
- Treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion
Common side effects
- Increased intraocular pressure
- Cataract
- Glaucoma
Key clinical trials
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Triamcinolone vs. Laser for Diabetic Macular Edema (NA)
- Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- triamcinolone intravitreal injection CI brief — competitive landscape report
- triamcinolone intravitreal injection updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI
Frequently asked questions about triamcinolone intravitreal injection
What is triamcinolone intravitreal injection?
How does triamcinolone intravitreal injection work?
What is triamcinolone intravitreal injection used for?
Who makes triamcinolone intravitreal injection?
Is triamcinolone intravitreal injection also known as anything else?
What drug class is triamcinolone intravitreal injection in?
What development phase is triamcinolone intravitreal injection in?
What are the side effects of triamcinolone intravitreal injection?
Related
- Drug class: All corticosteroid drugs
- Manufacturer: Federal University of São Paulo — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of non-infectious uveitis affecting the posterior segment of the eye
- Indication: Drugs for Treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion
- Also known as: triamcinolone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing